BFC Planning’s Krystal Biotech KRYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.33K Buy
10
+8
+400% +$2.77K ﹤0.01% 2845
2026
Q2
$743 Sell
2
-4
-67% -$1.2K ﹤0.01% 3206
2026
Q1
$1.55K Buy
+6
New +$1.6K ﹤0.01% 2663
2025
Q2
– Sell
-61
Closed -$11K – 2768
2025
Q1
$11K Hold
61
– – ﹤0.01% 1726
2024
Q4
$9.6K Hold
61
– – ﹤0.01% 1787
2024
Q3
$11.1K Buy
+61
New +$11.8K ﹤0.01% 1702

Other funds holding KRYS

BFC Planning's KRYS Position: Q3 2026 in Review

BFC Planning increased its Krystal Biotech (KRYS) stake by 400% in Q3 2026, buying an estimated $2.77K and bringing the position to 10 shares worth $3.33K. The position accounts for ﹤0.01% of the portfolio, ranked #2845.

BFC Planning first reported a position in KRYS in Q3 2024 and has held it in 6 quarters since. The position peaked at $11.1K in Q3 2024. 353 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • BFC Planning held 10 shares of Krystal Biotech worth $3.33K as of Q3 2026.
  • BFC Planning bought 8 Krystal Biotech shares in Q3 2026, an estimated $2.77K.
  • Krystal Biotech made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2845 holding.
  • BFC Planning first reported a position in Krystal Biotech in Q3 2024 and has held it in 6 quarters since.
  • BFC Planning's Krystal Biotech position peaked at $11.1K in Q3 2024.
  • 353 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.